Xenon and Neurocrine Biosciences announced a partnership on August 12, 2025, allowing collaboration and milestone payments regarding Azetukalner, which is Xenon's lead pipeline candidate.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Xenon and Neurocrine Biosciences announced a partnership on August 12, 2025, allowing collaboration and milestone payments regarding Azetukalner, which is Xenon's lead pipeline candidate.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Xenon
nightclub in New York City
Nothing else this week.
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ZacksXenon Q2 Loss Wider Than Expected, Pipeline Development in Focus Xenon Pharmaceuticals XENE reported a loss of $1.07 per share for the second quarter of 2025, wider than the Zacks Consensus Estimate